Skip to content
Parakho

Laurus Labs Ltd

NSE LAURUSLABSBSE 540222lauruslabs.com

Q1 FY27, unaudited

Revenue
₹2,026.31 Cr
Profit after tax
₹362.07 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations2,026.31+29.10%6,812.90
Other income9.18−11.98%54.95
Total income2,035.49+28.83%6,867.85
Employee benefit expense258.70+20.44%895.45
Finance costs42.22−18.02%170.73
Depreciation & amortisation123.87+6.02%480.05
Total expenses1,554.13+14.63%5,685.97
Profit before tax481.36+114.68%1,181.88
Tax expense119.37+89.06%292.03
Profit after tax362.07+123.94%890.14
Total comprehensive income359.86+123.56%884.24
Earnings per share
Earnings per share, basic₹6.81₹16.47
Earnings per share, diluted₹6.80₹16.45

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Laurus Labs reported Q1 FY27 revenue of INR2,026 crores, a 29% year-on-year increase, driven by growth in the CDMO segment and continued strength in the affordable medicines portfolio. EBITDA margin expanded to 31.8% and profit after tax was around INR368 crores, with management describing this as the highest quarterly revenue, EBITDA and profit for the company. Management also discussed capex plans, the CDMO and Bio segment updates, and progress on new modalities including ADCs, peptides and gene therapy.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 60 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 09 Oct 2026.